Selected Harvard Start-ups (1995-2007)
Economic Impact
Financing: $870MM (est. raised)
Number of Jobs Created: 490 (est.)
| Company | Year Founded (FY) | Harvard Inventor(s) | Harvard Technology | Company Location | Lead Investors |
| Curis, Inc. www.curis.com |
1995 | Douglas Melton, Andy McMahon, and Cliff Tabin | Drug discovery platform around Hedgehog and related pathways | Cambridge, MA | Biogen Idec, Charles River Ventures, Flagship Ventures, Highland Capital |
| Enanta Pharmaceuticals www.enanta.com |
1998 | Gregory Verdine | Platform for the synthesis of compounds with peptide characteristics | Watertown, MA | Lux Venture Capital, Oxford Bioscience Partners |
| Surface Logix, Inc. www.surfacelogix.com |
2000 | George Whitesides | The use of softlitography to make cell based assays for drug discovery and development | Brighton, MA | ARCH Venture Partners, Intel Capital, Venrock Associates |
| BioMimetic Therapeutics www.biomimetics.com |
2001 | Harry Antoniades | Technologies for wound healing and bone regeneration | Franklin, TN | Axiom Venture Partners, InterWest Partners, Mitsubishi International |
| Nantero www.nantero.com |
2001 | Charles Lieber | Using carbon nanotubes as a basis for a new form of nonvolatile memory | Woburn, MA | Globespan Capital Partners, Charles River Ventures, Draper Fisher Jurvetson, Stata Venture Partners |
| Nanosys www.nanosysinc.com |
2002 | Charles Lieber | Inorganic nanowires as components in various types of devices | Palo Alto, CA | ARCH, Polaris Venture Partners, Venrock Associates, Prospect Venture Partners, Lux Capital |
| Vitae Pharmaceuticals www.vitaepharma.com |
2002 | Eugene Shakhnovich | Novel algorithm for small molecular ligand design for drug development | Fort Washington, PA | Atlas Ventures, Prospect Venture Partners, Venrock Associates, Glaxo Smith Kline. |
| PharmAthene www.pharmathene.com |
2002 | John Collier | Dominant-negative mutant toxin proteins useful for the prevention and/or emergency treatment of anthrax infection | Annapolis, MD | Bear Stearns Health Innoventures, HealthCare Ventures |
| Infinity Pharmaceuticals www.ipi.com |
2003 | Stuart Schreiber | Platform for synthesizing libraries of compounds | Cambirdge, MA | Advent Venture Partners, Venrock Associates, Prospect Venture Partners, Novartis Bioventure Fund |
| Peptimmune, Inc. www.peptimmune.com |
2003 | Jack Strominger; Hidde Ploegh | Copolymers for supression of diabetes | Cambridge, MA | Genzyme, Vanguard Ventures |
| Ensemble Discovery Corp. www.ensemblediscovery.com |
2003 | David Liu | DNA Programmed Chemistry technology for chemical synthesis | Cambridge, MA | Flagship Ventures, ARCH Venture Partners, Oxford Bioscience Partners |
| Codon Devices, Inc. www.codondevices.com |
2005 | George Church | The technology enables the accurate and inexpensive assembly of long DNA molecules useful in cell engineering and whole genome sequencing applications | Cambridge, MA | Flagship Ventures, Kleiner Perkins Caufield and Byers, Alloy Ventures, Khosla Ventures |
| Sirtris Pharmaceuticals, Inc. www.sirtrispharma.com |
2005 | David Sinclair | Drug discovery platform and lead compounds around sirtuins for the treatments of age related disorders | Cambridge, MA | Polaris Venture Partners, Skyline Ventures |
| NanoTerra www.nanoterra.com |
2005 | George Whitesides | Key technologies in soft litography, self-assembly, surface chemistry, and fluidics and their application to new manufacturing techniques | Cambridge, MA | Private investors |
| Raindance Technologies raindancetechnologies.com |
2006 | David Weitz | Novel microfluidic techniques for droplet manupalutation for high throughput screening | Guilford, CT | Private investors |
| SiOnyx | 2006 | Eric Mazur | A new type of material that absorbs light very efficiently and can be used in a variety of applications | Cambridge, MA | Harris & Harris Group (NY) |
| Syndexa Pharmaceuticals www.syndexa.com |
2006 | Gokhan Hotamisligil | Portfolio of drug targets, assays and lead compounds for the treatment of metabolic diseases | Cambridge, MA | private |
| Claros Diagnostics www.clarosdx.com |
2007 | George Whitesides | A portable microfluidic diagnostic device | Woburn, MA | Oxford Bioscience Partners |
| Aileron Therapeutics www.aileronrx.com |
2007 | Gregory Verdine | Harvard licensed its core platform technology for turning peptides into drugs | Cambridge, MA | Apple Tree Partners, Novartis Bioventure Fund |
| Tetraphase Pharmaceuticals | 2007 | Andrew Myers | A technology for the total synthesis of tetracyclines by enabling their synthesis from simple building blocks | Watertown, MA | Mediphase Venture Partners, Fidelity Biosciences, Skyline Ventures, Flagship Ventures |